References
- Albaaj F, Hutchison AJ. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int J Clin Pract 2005;59:1091-1096.
- Hutchison AJ, Wilson RJ, Garafola S, et al. Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton) 2016;21:987-994.
- Makino M, Kawaguchi K, Shimojo H, et al. Extensive lanthanum deposition in the gastric mucosa: the first histopathological report. Pathol Int 2015;65:33-37.
- Iwamuro M, Urata H, Tanaka T, et al. Review of the diagnosis of gastrointestinal lanthanum deposition. World J Gastroenterol 2020;26:1439-1449.
- Kim SY, Lee JH, Lee SK. Gastric mucosal calcinosis. Korean J Gastroenterol 2017;70:208-210.
- Kim GH. Proton pump inhibitor-related gastric mucosal changes. Gut Liver 2021;15:646-652.
- Kim GH. Clinicians should be aware of proton pump inhibitor-related changes in the gastric mucosa. Clin Endosc 2024;57:51-52.
- Kubo K, Kimura N, Kato M. Potassium-competitive acid blocker-associated gastric mucosal lesions. Clin Endosc 2024 Feb 29 [Epub]. https://www.doi.org/10.5946/ce.2023.279
- Nishida S, Ota K, Hattori K, et al. Investigation of the clinical significance and pathological features of lanthanum deposition in the gastric mucosa. BMC Gastroenterol 2020;20:396.
- Nakamura T, Tsuchiya A, Kobayashi M, et al. M2-polarized macrophages relate the clearance of gastric lanthanum deposition. Clin Case Rep 2019;7:570-572.